Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Micronutrients

All Drugs and Chemicals

Pharmaceutical Solutions

Gastrointestinal Agents

Vitamins

Ascorbic Acid

Laxatives

Polyethylene glycol 3350

Sodium sulfate

Cathartics

Vitamin C

Fixed evening dose plus alternative morning dose

Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

NER1006

Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.

Moviprep

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.

Rodica Cinca, MD

This study is to investigate the effect of various modified low volume polyethylene glycol (PEG) 3350 and ascorbic acid/ascorbate (PEG+ASC)-based gut cleansing solutions on stool output in healthy subjects. In addition, the study is to assess and compare the safety and tolerance of the modified PEG+ASC formulations following oral administration with the safety profile of MOVIPREP®.

Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects

Stool weight output generated from the start of intake for the following 24 hours.

Concentration of PEG3350 in blood, urine and faeces.

Concentration of ascorbic acid in blood, urine and faeces.

Concentration of electrolytes in blood, urine and faeces.

Spontaneouly reported adverse events will be recorded throughout the study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects	NCT01834742	Colorectal Canc...	NER1006 NER1006 NER1006 Moviprep NER1006 NER1006 NER1006 NER1006	18 Years - 45 Years	Norgine
Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects	NCT01834742	Colorectal Canc...	NER1006 NER1006 NER1006 Moviprep NER1006 NER1006 NER1006 NER1006	18 Years - 45 Years	Norgine

Spots Global Cancer Trial Database for stool output

Every month we try and update this database with for stool output cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.